TEL AVIV, Israel and PARSIPPANY, New Jersey, USA, November 18, 2026
Teva Pharmaceutical Industries Ltd. has announced a major leadership transition within its global research and development (R&D) organisation, confirming that Dr. Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer, will leave the company after accepting an external opportunity. The announcement marks an important organisational development for the global pharmaceutical company as it continues to advance its innovative medicines pipeline and execute its long-term growth strategy. Teva stated that Dr. Hughes will remain involved over the coming months to support a smooth transition. The company has also initiated a comprehensive search for a permanent successor to lead its global R&D operations.
David Gardiner to Lead R&D During Transition
Following the announcement, Dr. David Gardiner, Head of Innovative Medicines and Clinical Development, has been appointed as the R&D transition lead, effective immediately. He will report directly to Richard Francis, President and Chief Executive Officer of Teva, until a permanent successor is appointed. The company confirmed that the search for a new R&D leader has already begun. The transition arrangement is intended to maintain leadership continuity across Teva’s research and development activities while the organisation identifies a suitable candidate for the permanent position. Dr. Gardiner’s existing responsibilities in innovative medicines and clinical development place him within the company’s research and clinical development leadership structure. His interim appointment is particularly relevant as Teva continues to progress its development programmes and strengthen its position in the innovative biopharmaceutical sector. Dr. Hughes’ departure follows his contributions to the transformation of Teva’s R&D organisation, including the development of its research pipeline, capabilities and scientific teams. According to CEO Richard Francis, the organisation is well positioned for its next phase of development, supported by the foundation established under the outgoing R&D leader.
Teva Maintains Its R&D Strategy and Pipeline Priorities
Despite the leadership change, Teva confirmed that its research and development strategy, priorities and financial expectations remain unchanged. The company intends to continue executing the commitments presented during its R&D Day on November 11, 2026, with a continued focus on advancing its innovative medicines pipeline. The announcement is significant because leadership changes at pharmaceutical companies can attract attention from investors, researchers, clinical development professionals and industry stakeholders who follow long-term drug development programmes. However, Teva has specifically stated that the transition does not represent a change in its existing strategic direction. The company continues to pursue opportunities across areas including neuroscience and immunology, alongside its established generics, complex generics and biosimilars businesses. Its broader portfolio reflects a combination of innovative drug research, clinical development and commercial pharmaceutical operations. Maintaining continuity across these activities will be important as the company works towards its previously communicated development and business objectives. Teva has not announced any new changes to individual clinical programmes or research priorities as part of this leadership update.
Innovative Medicines Revenue Target Remains in Focus
A key element of Teva’s long-term strategy is its ambition to generate US$6 billion to US$7 billion in innovative medicines revenue by 2030. The company reiterated this target in its leadership announcement, linking the ongoing R&D transition with the commitments outlined at its recent R&D Day. Achieving this ambition will depend on continued pipeline development, successful clinical and regulatory progress, commercial execution and the company’s ability to expand its innovative medicines portfolio. Teva’s research organisation therefore remains central to its broader Pivot to Growth strategy, which is intended to strengthen the company’s position as an innovative biopharmaceutical business while maintaining its global generics operations. The leadership transition comes at a time when the company is seeking to build momentum across its innovative pipeline and deliver on its longer-term business goals. Although the appointment of an interim R&D lead provides an immediate transition structure, the permanent successor will take on responsibility for guiding the organisation’s future research and development activities once appointed.Overall, Teva’s announcement represents a significant corporate leadership development rather than a change in its drug-development strategy. With David Gardiner leading the R&D transition and the search for a permanent successor underway, the company has stated that its pipeline priorities, strategic direction and 2030 innovative medicines revenue ambition remain intact. The coming months will be important for maintaining continuity across its global research and clinical development operations as Teva moves into its next phase of growth.
Source: Teva Pharmaceutical Inc press release



